Introduction
============

Colorectal cancer (CRC) is a common malignancy of the gastrointestinal tract, which is fourth in incidence and second in terms of cancer-related mortality in America ([@b1-mco-0-0-665]). Several factors and genes are associated with the process of tumor angiogenesis, invasion, growth and metastasis in CRC. A number of stage III/IV patients succumb to metastasis and stage II patients to recurrence, particularly in the liver, lungs and lymph nodes ([@b2-mco-0-0-665]). Despite the advances in identifying high-risk factors for recurrence in stage II CRC patients, the benefit from chemotherapy administration remains uncertain ([@b3-mco-0-0-665]--[@b5-mco-0-0-665]).

Over the last few decades, microsatellite instability (MSI) has been identified as a biomarker in previous clinical trials ([@b4-mco-0-0-665],[@b5-mco-0-0-665]), which demonstrated that patients with MSI treated with 5-fluorouracil exhibited a significant survival benefit compared with the non-MSI and the surgery alone groups. Numerous tumor cell-derived factors and microenvironment molecules, such as chemokines, are involved in cancer cell metastasis and migration ([@b6-mco-0-0-665],[@b7-mco-0-0-665]). Chemokines (8--10 kDa) are chemotactic cytokines that cause directed migration of numerous cells, including leukocytes, and are induced by inflammatory cytokines, growth factors and pathogenic stimuli. The chemokine-receptor axis allows cells to move towards high local concentrations of chemokines during inflammation, as well as the homeostatic transport of lymphocytes and dentritic cells. To date, \>50 chemokines and 20 seven-transmembrane-domain receptors, which belong to G-protein coupled families, have been identified. One receptor may generally bind to more than one cytokines. A number of human cancers characterized by leukocyte infiltration possess a complex chemokine network that affects tumor cell growth, survival, infiltration, migration and angiogenesis.

Latest research demonstrated that the expression of the majority of chemokines and their receptors, such as CXCL10/CXCR3, CXCL12/CXCR4, CCL21/CCR7 and CCL25/CCR9, is associated with CRC. Dwinell *et al* ([@b8-mco-0-0-665]) reported that CXCR3 is not present in normal colonic epithelial cells, but in mononuclear cells in the lamina propria. Kawada *et al* ([@b9-mco-0-0-665]) observed that CXCL10 enhances CRC cell survival and gelatinase expression in culture and upregulates cell surface expression of CXCR3. Furthermore, CXCL10 has been found to be overexpressed in several cases of CRC as a Ras target gene ([@b10-mco-0-0-665]), although Jiang *et al* ([@b11-mco-0-0-665]) reported opposite findings. It appears that chemokines exert their tumor-associated activies by inducing immune-stimulating and angiostatic effects and constituting the tumor microenviroment. However, the precise role of CXCL10/CXCR3 in solid cancers remains poorly understood.

The aim of the present study was to investigate CXCL10 and CXCR3 expression in stage II CRC, in order to determine its clinicopathological significance and role in disease recurrence and optimise postoperative treatment in patients with stage II CRC.

Patients and methods
====================

### Patients and materials

A series of 401 stage II CRC patients who underwent radical resection at Tianjin Medical University Cancer Institute and Hospital between 2005 and 2009 were included in this study. None of the patients had received preoperative neoadjuvant chemotherapy or radiotherapy. The patients were divided into two groups, the recurrence group (RG) and the non-recurrence group (NRG). We collected paraffin-embedded samples from 71 recurrent cases, 12 non-recurrent cases and 10 normal tissue samples. All the samples were independently reviewed by two pathologists and the histological diagnoses were classified according to the 2010 World Health Organization Classification of Digestive System Tumors ([@b12-mco-0-0-665]). The recurrence risk factors of stage II CRC according to the guidelines of the National Comprehensive Cancer Network included poor differentiation, lymph node or blood vessel infiltration, intestinal obstruction, \<12 lymph nodes retrieved, perineural invasion, partial perforation and positive resection margin. The term inflammatory adhesions refers to tumors found to be attached to the surrouding tissues during surgery, although no cancer cell infiltration is later identified on pathological examination.

### Immunohistochemical analysis

Tumor samples were collected from the Tianjin Medical University Cancer Institute and Hospital (Tianjin, China), fixed in formalin, embedded in paraffin and sectioned at 4 µm. A polyclonal rabbit anti-human CXCL10 antibody (cat. no. (C-20) sc-6226; dilution, 1:120; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and polyclonal rabbit anti-human CXCR3 antibody (cat. no. sc-101500; dilution, 1:200) were separately added to the sections following deparaffinization, hydration, antigen repair and endogenous peroxidase blocking. Immunoperoxidase staining was performed with the two-step EnVision™ method (DakoCytomation, Glostrup, Denmark) according to the manufacturer\'s instructions and visualized with 3,3′-diaminobenzidine (Sigma, St. Louis, MO, USA). The phosphate-buffered saline buffer was used to prepare negative control samples. Cell membrane and cytoplasmic staining were measured for these antibodies. Two pathologists independently counted the positive cells. The 4-tiered scoring system (−/+/++/+++), which took into account the percentage of positive cells and staining intensity, was used in our evaluation. The expression level of a certain target was determined according to the respective median values of a tumor indicator. Lower than the median was defined as 'low expression' and higher as 'strong expression'.

### Follow-up

Follow-up data were collected through telephone communication and from the database of the Medical Records Department of our hospital. The time interval from the operative date to clinical relapse was defined as the disease-free survival (DFS), and to death or last follow-up as overall survival (OS).

### Statistical analysis

All the data were analyzed using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). The t-test and analysis of variance were used for numerical variables and the χ^2^ test for qualitative variables. For survival analysis, survival curves were generated by the Kaplan-Meier method. The univariate survival analysis was performed using the log-rank test and the multivariate Cox proportional hazards model was used to identify the independent prognostic factors. P\<0.05 was considered to indicate statistically significant differences.

Results
=======

### Clinicopathological characteristics

A total of 229 male and 172 female patients, aged 7--87 years (mean age, 60.5 years), were initially included in the study. Of these, 54.86% (220/401) had colon cancer, 45.89% (181/401) had rectal cancer. Patients with colon cancer exhibited a survival advantage compared with those with rectal cancer (P=0.026). The general classification was ulcerated type in 288/401, elevated type in 111/401, colloid type in 1/401 and infiltrative type in 1/401. The pathological results of all kinds of carcinomas were adenoma, histologically classified as tubular (n=198), papillary (n=15), mucinous (n=25) and mixed (n=54). Of the 401 cases, 22 were classified as well-differentiated, 335 as moderately differentiated and 44 as poorly differentiated. A maximum diameter of \>10 cm was observed in 4.99% (20/401) of the cases, with a significantly different DFS compared with cases with smaller tumors (P\<0.051). In 91 cases, inflammatory adhesions to the surrounding tissues were identified, which statistically significantly affected OS (P=0.024), but not DFS (P=0.214). A backward Cox\'s proportional hazards regression analysis of the clinicopathological parameters yielded a hazard ratio of 1.823 (95% confidence interval: 1.093--3.039; P=0.013) for adhesion-positive compared with adhesion-negative patients. Patients with more risk factors exhibited shorter DFS and OS (P\<0.05). The multivariate Cox analysis indicated that location, tumor size and the number of high-risk factors were independent variables (P=0.013, 0.033 and 0.036), as was the presence of inflammatory adhesions, and were all significant prognostic factors for poor OS ([Table IA and B](#tI-mco-0-0-665){ref-type="table"}). Colon cancer patients with larger tumors who had \>1 high-risk factor and inflammatory adhesions were more likely to succumb to the disease.

From the follow-up data, we identified 106 patients with relapse or metastasis, with a median DFS of 21.8 months and a median OS of 39.6 months. The follow-up time ranged from 2 to 36 months. Of the 401 patients, 286 survived without evidence of cancer, 39/401 remained alive with recurrent lesions, 67/401 succumbed to CRC and 9/401 succumbed due to other causes.

### Inflammatory adhesions

In the RG, only the presence of inflammatory adhesions was associated with OS (P=0.025) ([Table II](#tII-mco-0-0-665){ref-type="table"}). However, there was no such association with the remaining characteristics. A total of 28 (28/106) of the relapsed patients exhibited inflammatory adhesions surrounding the tumor and the majority survived for \<3 years \[67.86 (19/28)\]. The median survival time of relapsed patients with adhesions was 26.63 months, while in the NRG it was 61.67 months. It is considered that adhesion had been reported previously to OS. It was concluded that the presence of inflammatory adhesions in a proportion of the patients was not associated with recurrence, but was closely associated with OS; however, for patients who presented with adhesions as well as recurrence, the prognosis was worse.

### Immunohistochemistry (IHC) in CRC

Immunostaining with anti-CXCL10 or -CXCR3 was considered to be antibody-specific by using the immunising peptide for each antibody as the target. In order to elucidate the association between clinical characteristics and the CXCL10/CXCR3 axis, we examined 143 CRC specimens and 10 peritumoral tissues at a distance of ≥5 cm from the resection margin (normal intestinal epithelia). CXCL10 and CXCR3 exhibited distinct characteristics in each group ([Fig. 1](#f1-mco-0-0-665){ref-type="fig"}).

As determined by IHC, CXCL10 was poorly expressed in 36 out of 72 cases (50.0%) in NRG and 19 out of 71 cases (26.76%) in RG, as well as strongly expressed in 10 out of 72 cases (13.89%) in the NRG and 27 out of 71 cases (38.03%) in the RG. We also found that 48 samples (66.67%) exhibited low CXCR3 expression in the NRG and 21 samples (29.58%) in the RG, whereas 12 cases (16.90%) exhibited high CXCR3 expression in the RG and 2 (2.78%) in the NRG. In the normal group, none of the normal tissue samples expressed CXCR3, whereas 6 samples poorly expressed CXCL10. The remaining pathological sections were not stained by the specific antibodies ([Tables III](#tIII-mco-0-0-665){ref-type="table"} and [IV](#tIV-mco-0-0-665){ref-type="table"}). There was a significant difference beween normal tissues and CRC RG or NRG in terms of CXCL10 and CXCR3 expression (P\<0.05).

### Effect of clinicopathological characteristics and biomarker expression on survival

The univariate variables were discussed and analyzed at the beginning of this research. We aimed to determine the association between prognosis and the expression of CXCL10 or CXCR3 with the assistance of Kaplan-Meier plots. High expression of CXCR3 was found to be associated with shorter OS and DFS (both P-values \<0.0001; [Fig. 2](#f2-mco-0-0-665){ref-type="fig"}, [Table V](#tV-mco-0-0-665){ref-type="table"}). However, CXCL10 expression was significantly associated with DFS (P\<0.0001), but not with OS (P=0.181) ([Table V](#tV-mco-0-0-665){ref-type="table"}). Further analysis demonstrated that general classification and the presence of inflammatory adhesions were correlated with CXCR3 (χ^2^=7.074, P=0.029) and CXCL10 (χ^2^=4.863, P=0.088). The fact that ulcerated CRCs stained deeper compared with elevated CRCs may be attributed to CXCR3, as one of the common inflammatory cytokines, being involved in ulcer-related inflammation.

### Effect of inflammatory adhesions and CXCR3 expression on survival

Of the 401 stage II CRC patients, 91 had inflammatory adhesions, of whom 28 patients developed disease recurrence ([Table IA](#tI-mco-0-0-665){ref-type="table"}). All the recurrent tumors with inflammatory adhesions were collected for IHC. In view of the results of the log-rank test, we found that the presence of inflammatory adhesions was associated with OS and CXCR3 expression; therefore, the statistical significance of the association was investigated. Under the same conditions of cancer surrounded by adhesions, patients with lower CXCR3 expression exhibited a better OS. However, patients with the same expression level of CXCR3 and different inflammatory adhesion status exhibited no differences in terms of OS (P\>0.05). On multivariate analysis, only CXCR3 expression (P=0.003) was found to be an independent factor predicting a poorer prognosis ([Fig. 3](#f3-mco-0-0-665){ref-type="fig"}).

Discussion
==========

In this study, we first analyzed the clinicopathological characteristics of stage II CRC and found that colon cancer, a higher number of risk factors, the presence of inflammatory adhesions and tumor size were associated with OS and were independent variables; the presence of inflammatory adhesions, in particular, was found to be a significant factor for recurrent patients. Subsequently, we further investigated the association between the CXCL10/CXCR3 axis and inflammatory adhesions and observed that strong CXCL10 or CXCR3 expression in stage II CRC patients predicted short DFS and OS, particularly CXCR3 expression, which exhibited statistical significance. Furthermore, CXCR3 was found to be closely associated with inflammatory adhesions and OS. We suggest that CXCR3 is a strong indicator of relapse in stage II CRC patients; in addition, CXCR3 was a long-term prognostic biomarker for relapsed stage II patients. The chemokine axis CXCL10/CXCR3 may be the molecular mechanism underlying the development of inflammatory adhesions.

The morbidity and mortality of CRC are on the increase worldwide. Chemokines, as inflammatory cytokines, were first investigated in the context of hematological diseases ([@b13-mco-0-0-665]), such as primary thrombocythemia, leukemia, multiple myeloma and von Willebrand syndrome. The association of chemokines with cancer has been attracting increasing attention. Schimanski *et al* ([@b14-mco-0-0-665]) and Ottaiano *et al* ([@b15-mco-0-0-665]) used IHC to detect CXCL12/CXCR4 expression in CRC and reported significantly higher expression in stage III/IV compared with stage I/II disease, suggesting that high expression was associated with lymph node and distant metastasis. Similar findings were reported for CCR7 in CRC ([@b16-mco-0-0-665],[@b17-mco-0-0-665]), breast cancer ([@b18-mco-0-0-665]) and pancreatic cancer ([@b19-mco-0-0-665]). Chemokines in tumors mainly function in two ways: They either alter tumor cell actin aggregation, increase or decrease the formation of pseudopodia and affect tumor cell migration, or they promote the secretion of certain cytokines, such as metalloproteinases, degrade the extracellular matrix, damage the endothelial cells and alter vascular permeability, thereby affecting the process of invasion or metastasis.

CXCL10 belongs to the ELR (Glu-Leu-Arg) motif-negative subfamily and acts as an angiogenesis inhibitor; it has also been characterized as a prognostic marker predicting clinical outcome in uterine cervical cancer ([@b20-mco-0-0-665]) and melanoma ([@b21-mco-0-0-665]). It has been demonstrated that CXCL10 exerts its antitumor effect through its immune-stimulating and angiostatic properties. Of note, the additional roles of CXCL10 in the tumor microenvironment are also important. CXCL10 may activate RhoA and Racl and trigger migration of cancer cells ([@b22-mco-0-0-665]). The CXCL10/CXCR3-mediated chemotaxis was found to promote lymph node metastasis in CRC by Kawada *et al* ([@b9-mco-0-0-665]). As one of the first immune defense components, CXCL10 levels increase sharply in the liver, lungs and lymph nodes in CRC by combining to its specific receptor CXCR3. In order to elucidate the mechanism of action, previous researchers constructed a CRC cell metastasis model and found that cells from both primary and metastatic lesions expressed increased levels of CXCL10 and CXCR3 ([@b23-mco-0-0-665],[@b24-mco-0-0-665]); they confirmed that tumor cells are able to activate and increase the level of lymphocytes in the microenviroment, upregulate the expression of interferon-γ and promote secretion of chemokine axes such as CXCL10/CXCR3, which is a cascade reaction. The underlying molecular mechanism may be CXCL10 promoting the CRC cells to secrete matrix metalloproteinases (MMPs) by inhibiting extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation and repressing the ERK signaling pathway. The MMPs may initiate other metastasis-related pathways or alter the adhesive properties of cancer cells, directly promoting invasion. Metzner *et al* ([@b25-mco-0-0-665]) previously analyzed the expression of chemokines in melanoma cells by flow cytometric measurements, ELISA and reverse transcription polymerase chain reaction; they hypothesized that constitutive chemokine expression enables an autocrine growth mechanism in epidermoid carcinoma cells. Numorous studies have demonstrated that CRC cells have the ability to secrete CXCL10 and CXCR3, whereas normal epithelial cells may not express CXCR3. In the present study, although CXCL10 as well as CXCR3 differed between RG and NRG, CXCL10 did not statistically significantly affect DFS or OS. As mentioned above, we hypothesized that the main function of CXCL10 expressed by stage II CRC cells is to promote the secretion of CXCR3 in an autocrine manner and initiate a cascade reaction, promoting invasion and distant migration of malignant carcinoma cells.

Regardless of the local or systemic inflammatory response, cancer-associated inflammation, another studying point, appears to be associated with tumor formation, progression and metastasis and may be of prognostic value in patients with CRC. Hu *et al* ([@b26-mco-0-0-665]) found that microbiota in the gastrointestinal tract may enhance the expression of chemokine CCL5 and induce CCL5-mediated inflammation, which in turn promotes epithelial cell proliferation through local activation of the interleukin 6 (IL-6) pathway, leading to tumorigenesis. Components of the gut microbiota may be associated with individual susceptibility. Through measuring IL-6, IL-10, neutrophil-lymphocyte ratio, neutrophil count and other inflammatory factors, it was previously demonstrated that elevated circulating IL-6 concentration is associated with tumor necrosis ([@b27-mco-0-0-665]). The key pathway may be Wnt signaling recognized by the transcription factor nuclear factor-κB ([@b28-mco-0-0-665]). There are no studies on the latent function of peritumoral imflammatory adhesions; however, the association between CXCR3 and inflammation is clear. Dysregulation of CXCR3 expression has been found in viral infections ([@b29-mco-0-0-665]), autoimmune diseases ([@b30-mco-0-0-665]), allergy and asthma. To the best of our knowledge, the present study is the first to provide supportive evidence for the hypothesis that CRC prognosis is associated with the presence of inflammatory adhesions and CXCR3 expression. In turn, the CXCL10/CXCR3 axis may participate in the peritumoral inflammatory response and promote tumor progression.

In conclusion, we observed that CXCL10 and CXCR3 are upregulated in recurrent CRC tissues. CXCR3 expression may be used as one of the predictors of prognosis in postoperative stage II CRC patients. The cause of adhesion formation remains unclear, but may pertain to the upregulated expression of CXCR3. Therefore, postoperative stage II CRC patients exhibiting strong expression of CXCR3 should be closely followed up.

![CXCL10 and CXCR3 membranous and cytoplasmic staining in colorectal tumors. (A) Low CXCL10 expression was demonstrated in 19/71 samples in the recurrence group (RG) and 36/72 samples in the non-recurrence group (NRG). (B) Strong CXCL10 expression was observed in 27/71 samples in the RG and 10/72 in the NRG. (C) Low CXCR3 expression was demonstrated in 21/71 samples in the RG and 48/72 in the NRG. (D) Strong CXCR3 expression was demonstrated in 12/71 samples in the RG and 2/72 in the NRG. (E) Low CXCL10 expression was demonstrated in 6/10 normal tissue samples. (F) Negative CXCR3 expression was demonstrated in 10/10 normal tissue samples.](mco-04-01-0023-g00){#f1-mco-0-0-665}

![Survival curve of CXCR3 expression. (A) Patients with strong expression (n=14) exhibited significantly shorter disease-free survival (DFS) compared with those with low expression (n=69, P\<0.0001, log-rank test) and negative expression (n=60, P\<0.0001, log-rank test); low vs. negative expression, P=0.012. (B) Patients with strong expression also exhibited significantly shorter overall survival (OS) compared with those with low expression (P\<0.0001) and negative expression (P\<0.0001); however, there was no significant difference between low and negative expression (P=0.184).](mco-04-01-0023-g01){#f2-mco-0-0-665}

![Kaplan-Meier analysis of cancer-specific overall survival (OS) of relapsed patients with stage II colorectal cancer subdivided by the presence of inflammatory adhesions and CXCR3 expression (P\<0.0001). Expression of CXCR3 (A) in cases without adhesions and (B) in cases with adhesions.](mco-04-01-0023-g02){#f3-mco-0-0-665}

###### 

Comparison of clinicopathological characteristics in stage II colorectal cancer patients undergoing potentially curative resection.

  A, Clinicopathological characteristics                                                                                                                                                                                         
  --------------------------------------------------------------------------------------------------------------------- -------- ------- ------- ------------------------------------------------------ --------- -------------- ------------------------------------------------------
  Gender                                                                                                                                         0.320                                                                           0.681
    Male                                                                                                                229      182     47                                                             167       62             
    Female                                                                                                              172      143     29                                                             128       44             
  Age, years                                                                                                                                     0.341                                                                           0.721
    ≤60                                                                                                                 199      166     33                                                             149       50             
    \>60                                                                                                                202      159     43                                                             146       56             
  Location                                                                                                                                       0.026^[b](#tfn2-mco-0-0-665){ref-type="table-fn"}^                              0.101
    Colon                                                                                                               220      187     33                                                             169       51             
    Rectum                                                                                                              181      138     43                                                             125       54             
  General classification                                                                                                                         0.551                                                                           0.515
    Ulcerated                                                                                                           288      229     59                                                             206       82             
    Elevated                                                                                                            111      94      17                                                             87        24             
    Other                                                                                                               2        2       0                                                              2         0              
  Tumor size, cm                                                                                                                                 0.031^[b](#tfn2-mco-0-0-665){ref-type="table-fn"}^                              0.051
    ≤10                                                                                                                 381      312     69                                                             283       98             
    \>10                                                                                                                20       13      7                                                              8         12             
  Stage                                                                                                                                          0.179                                                                           0.441
    IIA                                                                                                                 71       59      12                                                             55        16             
    IIB                                                                                                                 323      262     61                                                             236       87             
    IIC                                                                                                                 7        4       3                                                              4         3              
  Recurrence risk factors                                                                                                                        0.009^[b](#tfn2-mco-0-0-665){ref-type="table-fn"}^                              \<0.001^[b](#tfn2-mco-0-0-665){ref-type="table-fn"}^
    None                                                                                                                75       63      12                                                             56        19             
    1                                                                                                                   276      229     47                                                             208       68             
    ≥2                                                                                                                  50       33      17                                                             31        19             
  Preoperative CEA                                                                                                                               0.838                                                                           0.205
    Abnormal                                                                                                            28       23      5                                                              18        10             
    Normal                                                                                                              373      302     71                                                             277       96             
  Anemia                                                                                                                                         0.731                                                                           0.952
    No                                                                                                                  300      242     58                                                             221       79             
    Yes                                                                                                                 101      83      18                                                             74        27             
  Family history                                                                                                                                 0.528                                                                           0.295
    No                                                                                                                  327      263     64                                                             235       90             
    Yes                                                                                                                 74       62      12                                                             58        16             
  Inflammatory adhesions                                                                                                                         0.024^[b](#tfn2-mco-0-0-665){ref-type="table-fn"}^                              0.214
    No                                                                                                                  310      258     52                                                             232       78             
    Yes                                                                                                                 91       67      24                                                             63        28             
                                                                                                                                                                                                                                 
  B, Uni- and multivariate Cox proportional hazards model for overall survival in stage II colorectal cancer patients                                                                                                            
                                                                                                                                                                                                                                 
  Variables                                                                                                             B        SE      Wald    P-value^[a](#tfn1-mco-0-0-665){ref-type="table-fn"}^   Exp (B)   95% CI         
                                                                                                                                                                                                                                 
  Location                                                                                                              −0.622   0.250   6.184   0.013^[b](#tfn2-mco-0-0-665){ref-type="table-fn"}^     0.537     0.329--0.877   
  Tumor size                                                                                                            0.455    0.213   4.562   0.033^[b](#tfn2-mco-0-0-665){ref-type="table-fn"}^     1.577     1.038--2.395   
  Recurrence risk factors                                                                                               0.432    0.206   4.395   0.036^[b](#tfn2-mco-0-0-665){ref-type="table-fn"}^     1.540     1.029--2.307   
  Inflammatory adhesion                                                                                                 0.600    0.261   5.298   0.013^[b](#tfn2-mco-0-0-665){ref-type="table-fn"}^     1.823     1.093--3.039   

P-values were obtained with the log-rank and χ^2^ test in [Table IA](#tI-mco-0-0-665){ref-type="table"} and Cox regression in [Table IB](#tI-mco-0-0-665){ref-type="table"}.

P\<0.05, statistically significant. B, regression coefficient; SE, standard error; Exp, odds ratio; CI, confidence interval; CEA, carcinoembryonic antigen.

###### 

Correlation between the clinicopathological characteristics of relapsed patients and overall survival.

  Characteristics           P-value^[a](#tfn3-mco-0-0-665){ref-type="table-fn"}^
  ------------------------- ------------------------------------------------------
  Imflammatory adhesions    0.025^[b](#tfn4-mco-0-0-665){ref-type="table-fn"}^
  General classification    0.314
  Recurrence risk factors   0.194
  Tumor size                0.516
  Gender                    0.487
  Age                       0.931
  N stage                   0.266
  Preoperative CEA level    0.218
  Preoperative Hb level     0.295
  Tumor location            0.309
  Family history            0.859

P-values were obtained with Cox regression.

P\<0.05, statistically significant. CEA, carcinoembryonic antigen; Hb, hemoglobin.

###### 

Immunostaining for CXCL10 and CXCR3 expression in normal and CRC tissues.

                                                         CXCL10   CXCR3                                                                  
  ------------------------------------------------------ -------- ------- ---- ---- ---------------------------------------------------- ----
  CRC (n=143)                                            51       55      37   60   69                                                   14
  Normal tissue (n=10)                                   4        6       0    10   0                                                    0
  P-value^[a](#tfn5-mco-0-0-665){ref-type="table-fn"}^            0.145             0.002^[b](#tfn6-mco-0-0-665){ref-type="table-fn"}^   

P-values were obtained with the χ^2^ test.

P\<0.05, statistically significant. CRC, colorectal cancer.

###### 

Immunostaining for CXCL10 and CXCR3 in colorectal cancer (negative expression samples are absent).

  Variable              Recurrence group (n=71)   Non-recurrence group (n=72)   P-value^[a](#tfn7-mco-0-0-665){ref-type="table-fn"}^
  --------------------- ------------------------- ----------------------------- ------------------------------------------------------
  CXCL10                                                                        0.001^[b](#tfn8-mco-0-0-665){ref-type="table-fn"}^
    Low expression      19                        36                            
    Strong expression   27                        10                            
  CXCR3                                                                         \<0.001^[b](#tfn8-mco-0-0-665){ref-type="table-fn"}^
    Low expression      21                        48                            
    Strong expression   12                        2                             

P-values were obtained with the χ^2^ test.

P\<0.05, statistically significant.

###### 

Association between CXCL10/CXCR3 and prognosis

                      DFS^[a](#tfn9-mco-0-0-665){ref-type="table-fn"}^   OS^[a](#tfn9-mco-0-0-665){ref-type="table-fn"}^                      
  ------------------- -------------------------------------------------- ------------------------------------------------------- ------------ -------------------------------------------------------
  CXCR3 expression                                                       \<0.001^[c](#tfn11-mco-0-0-665){ref-type="table-fn"}^                \<0.001^[b](#tfn10-mco-0-0-665){ref-type="table-fn"}^
    Negative          42.46±3.30                                                                                                 67.12±3.75   
    Low               44.96±2.02                                                                                                 79.52±3.05   
    High              11.29±2.59                                                                                                 25.21±4.52   
  CXCL10 expression                                                      \<0.001^[c](#tfn11-mco-0-0-665){ref-type="table-fn"}^                0.181
    Negative          46.47±3.41                                                                                                 68.46±4.29   
    Low               51.93±3.48                                                                                                 59.83±2.54   
    High              28.66±3.25                                                                                                 61.79±5.62   

DFS and OS calculated as time (months).

P-values were obtained with the log-rank test.

P\<0.05, statistically significant. DFS, disease-free survival; OS, overall survival; SE, standard error.

[^1]: Contributed equally
